InsiderClue
Stocks · Health care · Surgical & Medical Instruments & Apparatus

Beta Bionics, Inc.

BBNX Clue Score57
United States Fiscal year ends December CIK 0001674632
$17.63 +1.15% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $17.63 −20.69% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 30 Jan 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue12.0Operating income−35.9Net income−44.1EPS, diluted−8.31Fiscal year 2024Revenue65.1 +442.9%Operating income−45.3Net income−54.8EPS, diluted−8.60Fiscal year 2025Revenue100.3 +53.9%Operating income−71.7Net income−73.2EPS, diluted−1.81
FY2023FY2024FY2025
Revenue 12.0 65.1 100.3
Growth +442.9% +53.9%
Operating income −35.9 −45.3 −71.7
Net income −44.1 −54.8 −73.2
Growth
EPS, diluted −8.31 −8.60 −1.81

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2023Gross margin52.6%Operating margin−298.9%Net margin−367.6%Free cash flow margin−273.8%Fiscal year 2024Gross margin55.1%Operating margin−69.5%Net margin−84.1%Free cash flow margin−79.3%Fiscal year 2025Gross margin55.4%Operating margin−71.5%Net margin−73.0%Free cash flow margin−56.1%
FY2023FY2024FY2025
Gross margin 52.6% 55.1% 55.4%
Operating margin −298.9% −69.5% −71.5%
Net margin −367.6% −84.1% −73.0%
Free cash flow margin −273.8% −79.3% −56.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−32.4Capital expenditure−0.4Free cash flow−32.8Fiscal year 2024Operating cash flow−48.3Capital expenditure−3.4Free cash flow−51.7Fiscal year 2025Operating cash flow−50.9Capital expenditure−5.3Free cash flow−56.2
FY2023FY2024FY2025
Operating cash flow −32.4 −48.3 −50.9
Capital expenditure −0.4 −3.4 −5.3
Free cash flow −32.8 −51.7 −56.2
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash26.6Shareholders’ equity−203.1Fiscal year 2024Cash30.4Shareholders’ equity−245.4Fiscal year 2025Cash31.6Shareholders’ equity287.6
FY2023FY2024FY2025
Cash 26.6 30.4 31.6
Shareholders’ equity −203.1 −245.4 287.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
52.6% 55.1% 55.4%
−298.9% −69.5% −71.5%
−367.6% −84.1% −73.0%
−273.8% −79.3% −56.1%
Spending
149.6% 40.2% 34.7%
101.9% 27.4% 30.9%
3.4% 5.2% 5.3%
Returns
n/a n/a −25.5%
−40.1% −36.6% −22.3%
Balance and payout
46.7% 49.2% 12.5%